Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis

World Journal of Gastroenterology

Volumn 7, Issue 3, 2001, Pages 363-369

  Nie, Q H ^a   Cheng, Y O ^a   Xie, Y M ^a   Zhou, Y X ^a   Cao, Y Z ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE PHOSPHOROTHIOIC ACID; COLCHICINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HUMAN SERUM ALBUMIN; PROCOLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; ELECTRON MICROSCOPY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC CODE; GENOME; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; LIVER FIBROSIS; NONHUMAN; NUCLEIC ACID PROBE; PHARMACOLOGICAL BLOCKING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY;

EID: 0034949533     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i3.363     Document Type: Article

References (67)

1. Study on activation and c-fos, c-jun expression of in vitro cultured human hepatic stellate cells
2. Dynamic changes of type I, III and IV collagen synthesis and distribution of collagen-producing cells in carbon tetrachloride-induced rat liver fibrosis
3. Study of heteroserum-induced rat liver fibrosis model and its mechanism
4. Effect of endotoxin on fibronectin synthesis of rat primary cultured hepatocytes
5. 1 and traditional medicine preparation
6. The cellular basis of hepatic fibrosis: Mechanism and treatment strategies
7. Effects of tetrandrine and verapamil on fibroblastic growth and proliferation
8. Effect of cordyceps polysaccharides - Liposome on the expression of interstitial mRNA in rats with hepatic fibrosis
9. Immunohistochemical study on basic fibroblast growth factor in experimental liver fibrosis
10. Relationship between tumor necrosis factor-α and liver fibrosis
11. Effect of selenium in rat experimental liver fibrosis
12. Studies on anti liver fibrosis of tetrandrine
13. Anti-hepatic fibrosis effect of pentoxifylling
14. Relationship between TGF-β1, serum indexes of liver fibrosis and hepatic tissue pathology in patients with chronic liver diseases
15. Mechanism and serum diagnosis of liver fibrosis
16. Relationship between ductule proliferation and liver fibrosis of chronic liver disease
17. Experimental study on serum fibrosis markers and liver tissue pathology and hepatic fibrosis in immuno-damaged rats
18. Gelatinase A proenzyme expression in the process of experimental liver fibrosis
19. Current situation in studies of gene therapy for liver cirrhosis and liver fibrosis
20. Action of cell factor and Decorin in tissue fibrosis
21. Relationship between serum TGF-β1 of chronic hepatitis B and hepatic tissue pathology and hepatic fibrosis quantity
22. Diagnosis and treatment of liver fibrosis
23. Molecular regulation of hepatic fibrogenesis
24. Signal transduction in hepatic stellate cells
25. Pathogenesis of liver fibrosis
26. Tissue inhibitors of metalloproteinases in liver fibrosis
27. Therapeutic strategy for liver fibrosis
28. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: A new role for homocysteine in liver fibrosis
29. Elevated serum type IV collagen: A sensitive indicator of the presence of cirrhosis in haemochromatosis
30. Tissue inhibitors of metalloproteinases: Role in liver fibrosis and alcoholic liver disease
31. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis
32. Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis
33. Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1
34. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
35. Antisense RNA and DNA
36. Therapeutic applications of oligonucleotide
37. Antisense treatment of viral infection
38. Gene inhibition using antisense Oligogeoxynucleotides
39. Recent advance in the therapy and prevention of CMV infections
40. Cloning of the cDNA encoding rat tissue inhibitor of metalloproteinase 1 (TIMP-1), aminoacid comparison with other TIMPs and gene expression in rat tissue
41. Study on experimental immunity model of hepatic fibrosis
42. Experimental study and clinical observation of hepatic fibrosis using different dosage form of compound Dan-Shen root
43. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver
44. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis
45. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis
46. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors
47. TIMP expression in toxic and cholestatic liver injury in rat
48. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease
49. Tissue inhibitor of metalloproteinase-1 and - 2 RNA expression in rat and human liver fibrosis
50. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response
51. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis
52. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon
53. Role of Ito cells in the degradation of matrix in liver
54. Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2
55. Structure of the extracellular matrix in normal and fibrotic: Collagen and glycoprotein
56. Repeated concanavalin A challenge in mice induces an interleukin 10-producing pherotype and liver fibrosis
57. The matrix-degrading metalloproteinases
58. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice
59. Experimental models of hepatic fibrosis: A review
60. Collagenases and liver fibrosis
61. Degradation of matrix proteins in liver fibrosis
62. Gene therapy for hepatic fibrosis-bringing treatment into the new millennium
63. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
64. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
65. Reversing liver cirrhosis: Impact of gene therapy for liver cirrhosis